Want to see IFRX full AI Analyst Report?
Top Page
InflaRx
(NASDAQ:IFRX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▲(14.94% Upside)
Action:Reiterated
Date:08/10/26
The score is primarily held back by very weak financial performance—persistent losses, minimal/volatile revenue, and ongoing negative free cash flow that may require future funding. Technicals are neutral-to-mixed with limited momentum, and valuation is constrained by a negative P/E and no dividend data.
Positive Factors
Conservative balance sheet with very low leverage
Very low financial leverage reduces refinancing and interest-rate risk, giving management flexibility to prioritize R&D and clinical programs. This conservatively levered position supports multi-month operational runway relative to highly indebted peers and lowers bankruptcy probability while they pursue development milestones.
Negative Factors
Persistent negative operating and free cash flow
Sustained negative operating and free cash flow signals the business is not self‑funding; this pattern drains reserves and forces recurring financing. Over a 2–6 month horizon, continued burn heightens the probability of new capital raises, which can constrain strategic options and delay development plans if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet with very low leverage
Very low financial leverage reduces refinancing and interest-rate risk, giving management flexibility to prioritize R&D and clinical programs. This conservatively levered position supports multi-month operational runway relative to highly indebted peers and lowers bankruptcy probability while they pursue development milestones.
Read all positive factors
InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$300.48M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding147,292,860
10 Day Avg. Volume939,464
30 Day Avg. Volume1,201,042
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside302.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$12.40K
InflaRx Business Overview & Revenue Model
Company Description
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical ro...
How the Company Makes Money
InflaRx is a clinical-stage biotech, so it typically does not have recurring commercial product sales unless it has an approved, marketed drug (null if not applicable). Its funding and revenue, when present, generally come from (1) collaboration a...
InflaRx Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -10.10K | 29.33K | 165.79K | 63.09K | 0.00 | 0.00 |
| Gross Profit | -4.87M | -7.24M | -3.15M | -469.17K | 0.00 | 0.00 |
| EBITDA | -38.79M | -45.16M | -45.55M | -42.06M | -28.84M | -44.94M |
| Net Income | -39.14M | -45.63M | -46.06M | -42.67M | -29.48M | -45.63M |
Balance Sheet | ||||||
| Total Assets | 166.84M | 55.19M | 76.02M | 120.21M | 102.40M | 125.14M |
| Cash, Cash Equivalents and Short-Term Investments | 158.45M | 46.44M | 18.38M | 12.77M | 81.81M | 83.41M |
| Total Debt | 832.83K | 897.53K | 805.09K | 1.12M | 1.36M | 1.43M |
| Total Liabilities | 20.72M | 13.65M | 14.60M | 17.63M | 14.05M | 19.86M |
| Stockholders Equity | 146.12M | 41.54M | 61.42M | 102.58M | 88.35M | 105.28M |
Cash Flow | ||||||
| Free Cash Flow | -23.96M | -34.03M | -48.60M | -37.89M | -33.91M | -39.97M |
| Operating Cash Flow | -23.83M | -33.92M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing Cash Flow | 29.75M | 3.11M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing Cash Flow | 127.60M | 32.00M | 386.45K | 52.99M | 1.94M | 61.58M |
InflaRx Technical Analysis
Positive
1.74
Price Trends
1.88
Positive
1.83
Positive
1.44
Positive
Market Momentum
0.02
Negative
62.22
Neutral
89.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Positive. The current price of 1.74 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.88, and above the 200-day MA of 1.44, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.22 is Neutral, neither overbought nor oversold. The STOCH value of 89.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IFRX.
InflaRx Risk Analysis
InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InflaRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $186.36M | 1.06 | 72.96% | ― | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $81.21M | -6.86 | 44.67% | ― | -96.72% | -253.97% | |
49 Neutral | $108.19M | -10.66 | -65.73% | ― | ― | 19.64% | |
48 Neutral | $300.48M | -3.61 | -58.00% | ― | ― | ― | |
46 Neutral | $193.09M | -1.63 | -136.27% | ― | ― | 27.94% | |
43 Neutral | $52.90M | -1.17 | 214.97% | ― | -31.12% | -35.10% |
* Healthcare Sector Average
IFRX
InflaRx
2.04
1.13
123.68%
ORMP
Oramed Pharm
4.48
2.54
131.05%
ATRA
Atara Biotherapeutics
8.09
-3.39
-29.53%
ANIX
Anixa Biosciences
3.18
0.20
6.71%
CLNN
Clene
4.14
-0.10
-2.36%
ABOS
Acumen Pharmaceuticals
2.67
1.24
86.71%
InflaRx Corporate Events
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K
Aug 6, 2026
InflaRx N.V. reported on August 6, 2026 that it has filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of August, covering its unaudited condensed consolidated financial statements for the three and six months ended Ju...
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos
Jun 30, 2026
On June 30, 2026, InflaRx said it is reviewing how to broaden its development and registration strategy for ANCA-associated vasculitis (AAV) in Europe. The move follows the June 26, 2026 recommendation by the EMA’s human medicines committee ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.